



NanoEcho AB and us4us Ltd. strengthen collaboration for future medical ultrasound technology

NanoEcho AB has signed a new letter of intent with us4us Ltd. regarding continued collaboration on the product development that was initiated with a letter of intent in July 2022. The collaboration is focused on the development of the next-generation ultrasound scanner module.

According to the previous agreement, NanoEcho AB entered an active collaboration with us4us Ltd. regarding the development of an innovative medical ultrasound scanner module intended for diagnostics. The aim is that the module will be included in NanoEcho's planned commercial diagnostic system for rectal cancer. In the continued collaboration, the companies intend to further develop the next generation of this module. The focus will be on improving performance, reducing energy consumption, and increasing cost efficiency. These improvements present exciting opportunities for NanoEcho's future medical diagnostic devices and ensure that, even after market launch, NanoEcho remains at the forefront of medical imaging technology.

"By collaborating on the development of next-generation ultrasound scanner modules, we ensure that our needs are included in future products. This partnership strengthens our potential to meet future challenges in medical imaging technology," says Linda Persson, CEO of NanoEcho AB, when she emphasizes the importance of the partnership.

"We believe that high-performance yet low-power software-defined ultrasound is the future of medical diagnostics, and our partnership with NanoEcho will help attain this future," says Marcin Lewandowski, CEO of us4us Ltd.

Press Release
01 September 2023 12:00:00 CEST



NANOECHO
next level diagnostics

For further information, please contact:

Kristina Hallström, CMO & CCO

email: ir@nanoecho.se

NanoEcho develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern patented ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se